

Apomorphine hydrochloride (Kynmobi®)

Place of Service

Office Administration (*for initial titration kit*)

HCPCS: J3490

NDCs:

- 63402-088-10: dose titration kit carton contains a total of 10 individually packaged sublingual films of:
 - Two single 10 mg films (NDC 63402-010-01)
 - Two single 15 mg films (NDC 63402-015-01)
 - Two single 20 mg films (NDC 63402-020-01)
 - Two single 25 mg films (NDC 63402-025-01)
 - Two single 30 mg films (NDC 63402-030-01)

Condition listed in policy (see criteria for details)

- [Parkinson's disease](#)

AHFS therapeutic class: Anti-Parkinson drug

Mechanism of action: Non-ergoline dopamine agonist

(1) Special Instructions and pertinent Information

Kynmobi® requests for the initial titration kit are managed under the Medical Benefit. Please submit clinical information for prior authorization review.

(2) Prior Authorization/Medical Review is required for the following condition(s)

All requests for apomorphine hydrochloride (Kynmobi®) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

Hypomobility associated with Parkinson's disease

1. Being recommended by a neurologist, AND
2. Patient experiences acute, intermittent episodes of hypomobility, "off" episodes associated with advanced Parkinson's disease, AND
3. Inadequate response or intolerance to at least one adjunctive therapy (e.g., COMT inhibitor, MAO-B inhibitor, dopamine agonist), or contraindication to all

Covered Dose

One titration kit

Coverage Period

One-time titration kit

(3) The following condition(s) DO NOT require Prior Authorization/Preservice

All requests for apomorphine hydrochloride (Kynmobi®) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

(4) This Medication is NOT medically necessary for the following condition(s)

Coverage for a Non-FDA approved indication, requires that criteria outlined in Health and Safety Code § 1367.21, including objective evidence of efficacy and safety are met for the proposed indication.

Please refer to the Provider Manual and User Guide for more information.

(5) Additional Information

How supplied:

- Titration kit contains: 10 individually packaged films of:
 - 2 – single 10 mg films
 - 2 – single 15 mg films
 - 2 – single 20 mg films
 - 2 – single 25 mg films
 - 2 – single 30 mg films
- 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg sublingual film

(6) References

- AHFS®. Available by subscription at <http://www.lexi.com>
- DrugDex®. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
- Kynmobi® (apomorphine hydrochloride sublingual film) [Prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 5/2022.
- Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease. Movement Disorders 2018.

(7) Policy Update

Date of last review: 4Q2022

Date of next review: 4Q2023

Changes from previous policy version:

No clinical change to policy following revision.

*BSC Drug Coverage Criteria to Determine Medical Necessity
Reviewed by P&T Committee*